IRIS
RIZZI, Rita
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 11.732
AS - Asia 5.855
EU - Europa 4.367
SA - Sud America 1.658
AF - Africa 289
OC - Oceania 14
Continente sconosciuto - Info sul continente non disponibili 10
Totale 23.925
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 11.547
SG - Singapore 2.510
CN - Cina 1.379
BR - Brasile 1.295
IT - Italia 962
HK - Hong Kong 751
SE - Svezia 669
RU - Federazione Russa 528
DE - Germania 460
UA - Ucraina 448
FI - Finlandia 383
FR - Francia 378
VN - Vietnam 365
GB - Regno Unito 249
IN - India 187
AR - Argentina 126
BD - Bangladesh 115
CI - Costa d'Avorio 97
CA - Canada 87
ID - Indonesia 78
TR - Turchia 70
IQ - Iraq 65
MX - Messico 59
CO - Colombia 54
ZA - Sudafrica 53
EC - Ecuador 51
NL - Olanda 51
IE - Irlanda 47
PL - Polonia 42
SA - Arabia Saudita 42
VE - Venezuela 42
JP - Giappone 41
PK - Pakistan 41
ES - Italia 34
MA - Marocco 33
CL - Cile 28
UZ - Uzbekistan 28
BE - Belgio 25
PY - Paraguay 25
TN - Tunisia 24
JO - Giordania 22
CZ - Repubblica Ceca 21
PE - Perù 20
EG - Egitto 19
PH - Filippine 18
MY - Malesia 14
AT - Austria 13
AU - Australia 13
ET - Etiopia 13
AE - Emirati Arabi Uniti 12
JM - Giamaica 12
AZ - Azerbaigian 11
KE - Kenya 11
LT - Lituania 11
IL - Israele 10
IR - Iran 10
KR - Corea 9
NP - Nepal 9
UY - Uruguay 9
KZ - Kazakistan 8
TH - Thailandia 8
BO - Bolivia 7
OM - Oman 7
PS - Palestinian Territory 7
CR - Costa Rica 6
GT - Guatemala 6
SN - Senegal 6
TW - Taiwan 6
BY - Bielorussia 5
EU - Europa 5
XK - ???statistics.table.value.countryCode.XK??? 5
AL - Albania 4
AO - Angola 4
DO - Repubblica Dominicana 4
DZ - Algeria 4
LY - Libia 4
MD - Moldavia 4
MU - Mauritius 4
RO - Romania 4
BG - Bulgaria 3
BN - Brunei Darussalam 3
CH - Svizzera 3
GE - Georgia 3
HN - Honduras 3
HU - Ungheria 3
LB - Libano 3
MN - Mongolia 3
MT - Malta 3
PT - Portogallo 3
SY - Repubblica araba siriana 3
TG - Togo 3
AM - Armenia 2
BH - Bahrain 2
BJ - Benin 2
CY - Cipro 2
DK - Danimarca 2
EE - Estonia 2
GA - Gabon 2
KG - Kirghizistan 2
KW - Kuwait 2
Totale 23.888
Salva come PNG Salva come JPEG
Città #
Singapore 1.317
Ashburn 1.090
Jacksonville 1.017
Chandler 1.011
Woodbridge 893
Fairfield 825
Hong Kong 730
San Jose 630
Houston 530
Nyköping 470
Ann Arbor 454
Cambridge 431
Seattle 332
Beijing 317
Wilmington 297
Roxbury 256
Lawrence 241
Nanjing 239
Lauterbourg 238
New York 192
Boardman 175
Los Angeles 163
Des Moines 161
Dallas 152
Bari 144
Helsinki 128
Ho Chi Minh City 124
Inglewood 107
Abidjan 96
São Paulo 95
Princeton 89
Brooklyn 77
Santa Clara 77
Buffalo 72
Hanoi 72
Shenyang 72
Hebei 66
Rome 63
London 60
Council Bluffs 55
San Diego 55
Jiaxing 52
Dearborn 51
Milan 50
Florence 48
Nanchang 46
Dublin 45
Munich 44
Changsha 41
Moscow 39
Rio de Janeiro 38
Falkenstein 37
Nuremberg 37
Tianjin 37
Jakarta 36
Paris 36
Guangzhou 33
Tokyo 33
Baghdad 32
Frankfurt am Main 32
Montreal 32
Johannesburg 31
Orem 31
Warsaw 29
Pune 28
Chennai 27
Belo Horizonte 26
Phoenix 26
Tashkent 26
Toronto 26
Turku 26
Brasília 25
Chicago 25
Curitiba 25
Atlanta 24
Brussels 24
Dhaka 22
Redwood City 22
Medellín 21
The Dalles 21
San Francisco 20
Denver 18
Istanbul 18
Jinan 18
Amsterdam 17
Manchester 17
Quito 17
Washington 17
Campinas 16
Noicattaro 16
Salvador 16
Shanghai 16
Amman 15
Guayaquil 15
New Delhi 15
Porto Alegre 15
Stockholm 15
Haiphong 14
Hefei 14
Jeddah 14
Totale 15.220
Salva come PNG Salva come JPEG
Nome #
Leucemia linfatica cronica in trasformazione prolinfocitoide: descrizione di un caso 202
LIGHT/TNFSF14 as a new biomarker of bone disease in multiple myeloma patients experiencing therapeutic regimens 193
"Real world" outcome of lenalidomide plus dexamethasone in the setting of recurrent and refractory multiple myeloma: Extended follow-up of a retrospective multicenter study by the "rete ematologica pugliese" 188
Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: a multicenter, retrospective real-world experience with 200 cases outside of controlled clinical trials 187
Carfilzomib-Lenalidomide-Dexamethasone (KRd) Induction-Autologous Transplant (ASCT)-Krd Consolidation Vs KRd 12 Cycles Vs Carfilzomib-Cyclophosphamide-Dexamethasone (KCd) Induction-ASCT-KCd Consolidation: Analysis of the Randomized Forte Trial in Newly Diagnosed Multiple Myeloma (NDMM) 179
Non-treatment-related chronic myeloid leukemia as a second malignancy 169
A role of light as potential biomarker for progression of smoldering to symptomatic multiple myeloma 166
Maintenance in myeloma patients achieving complete response after upfront therapy: a pooled analysis 165
TRAIL effect on osteoclast formation in physiological and pathological conditions 164
Vascular Endothelial Growth Factor Serum Levels Are Elevated in Patients with Hereditary Hemorrhagic Telangiectasia 160
CARFILZOMIB, LENALIDOMIDE AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS: THE REAL LIFE EXPERIENCE OF RETE EMATOLOGICA PUGLIESE (REP) 151
Alteration of the osteogenic properties of bone marrow stromal cells from multiple myeloma bone disease patients 150
A case of AL amyloidosis associated with IgD multiple myeloma (MM): clinical and laboratory findings, and outcome 149
Behçet's disease: an immune-mediated vasculitis involving vessels of all sizes 148
Amyloid in bone marrow smears of patients affected by multiple myeloma 148
Concomitant primary polycythemia vera and follicle center cell non-Hodgkin lymphoma: a case report and review of the literature 145
How Age, Comorbidities and Concomitant Medications Influence Ibrutinib Management and Survival in Waldenstrom Macroglobulinemia 145
Ofatumumab retreatment and maintenance in fludarabine-refractory chronic lymphocytic leukaemia patients 142
Light/TNFSF14 increases osteoclastogenesis and decreases osteoblastogenesis in multiple myeloma-bone disease. 142
ANALYSIS OF PROGNOSTIC FACTORS AND TIME TO FIRST TREATMENT IN YOUNG PATIENTS (<55 YEARS) WITH CHRONIC LYMPHOCYTIC LEUKEMIA: A SINGLE CENTER EXPERIENCE 141
Continuous therapy in standard- and high-risk newly-diagnosed multiple myeloma: A pooled analysis of 2 phase III trials 139
A case of light chain (AL) amyloidosis associated with IgD Multiple Myeloma (MM): clinical features, laboratory findings and outcome 135
Sclerostin is overexpressed by plasma cells from multiple myeloma patients 134
Alteration of bone remodeling in multiple myeloma bone disease: role of sclerostin 133
Analysis of percent identity of IGHV mutation as prognostic factor in CLL patients treated with fludarabine, cyclofosfamide and rituximab: a single centre experience 132
DARA-VD VERSUS DARA-RD AS SALVAGE THERAPY FOR PATIENTS WITH MYELOMA. INITIAL FOLLOW-UP OF AN ITALIAN MULTICENTER RETROSPECTIVE CLINICAL EXPERIENCE BY RETE EMATOLOGICA PUGLIESE 132
Autoimmune Myelofibrosis: report of three cases and review of the literature 131
A weekly infusion of bortezomib reduces peripheral neuropathy 130
LIGHT/TNFSF14 Promotes Osteolytic Bone Metastases in Non-small Cell Lung Cancer Patients 130
Early mortality in myeloma patients treated with first-generation novel agents thalidomide, lenalidomide, bortezomib at diagnosis: A pooled analysis 129
Another link between bone and immune system: LIGHT 127
Ibridizzazione in situ non isotopica. Attualità e prospettive 127
CD34CD2 Acute promyelocytic leukemia (APL): is this a distinct subset? 127
A rare case of IgM-Multiple Myeloma 127
Amyloidosis: clinical picture, immunological and biomolecular features, treatment prospects 125
Soluble Decoy Receptor 3 (DcR3) modulates the survival and formation of osteoclasts from multiple myeloma bone disease patients 125
Altered osteogenic properties of bone marrow stromal cells from multiple myeloma patients 125
Anti-endothelial cell antibodies (AECA) in a patient wiyh Takayasu’s arteritis. In: Pathogenesis and immunotherapy of autoimmune diseases. Final program and abstract book 124
Hepatitis C virus infection and mixed cryoglobulinemia: a striking association 124
Dedalo: Phase II Study of Daratumumab Plus Pomalidomide and Dexamethasone (DPd) in Patients with Relapsed/Refractory Multiple Myeloma and 17p Deletion 122
The role of multiparameter flow cytometry in the work-up of IGM-monoclonal gammopathies 122
Considerations in the treatment of multiple myeloma: a consensus statement from Italian experts 122
Takayasu’s arteritis: a cell mediated large vessel vasculitis 121
A prospective randomized study comparing rituximab and dexamethasone vs dexamethasone alone in ITP: results of final analysis and long term follow up 120
Autoimmune hemolytic anemia during interferon-alfa therapy for chronic hepatitis C 120
Rhabdomyolysis and acute tubular necrosis in coniine (hemlock)poisoning 119
Alterazione delle capacità osteogeniche in cellule stromali ottenute da midollo osseo di pazienti affetti da mieloma multiplo 117
A phase II study of chlorambucil plus rituximab followed by maintenance versus observation in elderly patients with previously untreated chronic lymphocytic leukemia: Results of the induction phase 117
SARS-CoV-2 Infection Incidence and Outcome Before and After Full Vaccination in Patients With Monoclonal Gammopathy of Undetermined Significance 116
REAL-WORLD ITALIAN EXPERIENCE OF POMALIDOMIDE IN RELAPSED-REFRACTORY MYELOMA: RETROSPECTIVE MULTICENTER STUDY BY THE RETE EMATOLOGICA PUGLIESE AND BASILICATA 116
Acute tubular necrosis in the hemlock poisoning 115
Schnitzler syndrome: validation and applicability of diagnostic criteria in real-life patients 115
Livelli sierici di VEGF in pazienti affetti da Sindrome di Rendu-Osler-Weber 114
The OPG/TRAIL complex in an in vitro osteoclastogenesis model derived from human multiple myeloma-bone disease 114
T cells support osteoclastogenesis in an in vitro model derived from human multiple myeloma bone disease: the role of the OPG/TRAIL interaction 114
A phase II study of chlorambucil + rituximab (CLB-R) followed by R maintenance vs observation in elderly patients with previously untreated chronic lymphocytic leukemia (CLL): induction phase results 113
DEDALO: PHASE II STUDY OF DARATUMUMAB PLUS POMALIDOMIDE AND DEXAMETHASONE (DPD) IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA AND 17P DELETION 112
In vitro osteoclastogenesis and T-cell RANKL expression in multiple myeloma-bone disease at diagnosis and in the setting of frontline treatment 112
Immunogenicity of two idiotypes with a different immunoglobulin-chain distribution expressed on the same anti-CD4 Mab 112
A phase II Study of chlorambucil plus rituximab followed by maintenance versus observation in elderly patients with previously untreated chronic lymphocytic leukemia: results of the first interim analysis 112
The role of OPG/TRAIL complex in multiple myeloma: the OPG/TRAIL complex in an in vitro osteoclastogenesis model derived from human multiple myeloma-bone disease 111
Anti-endothelial cell autoantibodies in patients with Behcet’s disease 109
Infection complications in patients with multiple myeloma treated with new drug combinations including thalidomide 109
LIGHT INVOLVEMENT IN MULTIPLE MYELOMA-OSTEOLYTIC BONE DISEASE 109
Malignant lymphoma involving a Warthin’s tumor: a case with immunophenotypic and gene rearrangement analysis 108
Irisin prevents trabecular bone damage and tumor invasion in a mouse model of multiple myeloma 108
The Role of LIGHT in Multiple Myeloma-Bone Disease 107
Daratumumab in light chain deposition disease: rapid and profound hematologic response preserves kidney function 107
Human anti-mouse antibodies interfere in the determination of sCD4 in intravenous immunoglobulin preparations 106
P-ANCA atipici nelle malattie infiammatorie croniche intestinali 106
A Phase III study of enoxaparin versus aspirin versus low-dose warfarin as thrombophylaxis for patients with newly diagnosed multiple myeloma treated up-front with thalidomide based-regimens 106
T cells support osteoclastogenesis in an in vitro model derived from psoritic arthritis 104
Bone marrow angiogenesis in autoimmune myelofibrosis 104
Myeloma cells suppress osteoblasts through sclerostin secretion 104
Angiogenesis and hereditary hemorrhagic telangiectasia. Rendu-Osler-Weber disease 104
DCR3 involvement in multiple myeloma bone disease 103
FLAG-IDA in the treatment of refractory/relapsed adult acute lymphoblastic leukemia 103
What Is New in the Treatment of Smoldering Multiple Myeloma? 103
T cells support the in vitro formation of osteoclasts in multiple myeloma-bone disease: the role of OPG/TRAIL interaction 102
Dexamethasone plus rituximab yields higher sustained response rates than dexamethasone monotherapy in adults with primary immune thrombocytopenia 101
Gemtuzumab ozogamicin with cytarabine and mitoxantrone as a third-line treatment in a poor prognosis group of adult acute myeloid leukemia patients: a single-center experience 101
L'AMILOIDOSI: QUADRI CLINICI, CARATTERISTICHE IMMUNOLOGICHE E BIOMOLECOLARI, PROSPETTIVE TERAPEUTICHE 100
Fludarabine, cyclophosphamide and lenalidomide in patients with relapsed/refractory chronic lymphocytic leukemia. A multicenter phase I–II GIMEMA trial 100
T cells support the osteoclastogenesis in an in vitro model derived from human multiple myeloma bone disease 99
[The emergency treatment of aneurysms of the supra-aortic trunks and of the internal carotid]. FT Il trattamento in urgenza degli aneurismi dei tronchi sovraortici e della carotide interna. 99
Failure of an in vitro model of osteoclastogenesis in human plasma cell leukaemia (PCL) 98
Autoimmune bone marrow fibrosis: a distinct clinicopathological entity 97
Chirurgia degli aneurismi dei tronchi sovraaortici 96
Clinical spectrum of accidental hemlock poisoning: neurotoxic manifestations, rhabdomyolysis and acute tubular necrosis 96
Circulating levels of cathepsin-k in multiple myeloma patients 96
The role of the Wnt-signaling antagonist Sclerostin in the development of osteolytic lesions in multiple myeloma 95
Infectious complications in patients with multiple myeloma treated with new drug combinations containing thalidomide 95
Aneurysms of the supra-aortic trunks in Takayasu's disease - Report of two cases 95
Myeloma cells induce osteoblast suppression through sclerostin secretion 95
Carfilzomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma patients: the real-life experience of Rete Ematologica Pugliese (REP) 95
Thalidomide, dexamethasone, doxil and velcade (ThaDD-V) induction therapy followed by consolidation-maintenance is very effective in early relapsed/refractory MM 94
Cost of illness in patients with multiple myeloma in Italy: the CoMiM study 94
Soluble CD4 antigen reactivity in intravenous immunoglobulin preparations: is it specific? 94
Microvessel density and angiogenic cytokine expression in autoimmune myelofibrosis compared with chronic idiopathic myelofibrosis 93
Schnitzler's syndrome: diagnosis, treatment, and follow-up. 93
Totale 12.174
Salva come PNG Salva come JPEG
Categoria #
all - tutte 100.127
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 100.127
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021483 0 0 0 0 0 0 0 0 0 242 151 90
2021/20221.790 78 253 7 128 56 77 73 96 126 79 314 503
2022/20232.648 380 231 111 271 344 375 41 300 495 16 45 39
2023/20241.332 200 212 73 66 97 238 65 69 8 55 101 148
2024/20254.078 114 55 403 140 110 366 310 344 182 187 622 1.245
2025/20267.432 1.181 365 575 970 859 524 1.094 258 873 733 0 0
Totale 24.265